Nucana   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Edinburgh United Kingdom (2008)

Organization Overview

First Clinical Trial
2012
NCT01621854
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

NuCana Biomed | NuCana BioMed Ltd. | NuCana plc

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Biliary Tract Neoplasms (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 2)

Lymphoma (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 12